Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999726 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BANPEPENPEPLTA4H | |
| SCHEMBL27999749 | 0.85 | FOLH1 (0.48) | ITGB3ITGA2BANPEPENPEPLTA4H | |
| SCHEMBL289030 | 0.85 | FOLH1 (0.48) | ITGB3ITGA2BANPEPENPEPLTA4H | |
| SCHEMBL8075751 | 0.83 | NOS3 (0.50) | ITGB3ITGA2BANPEPENPEPSLC1A2 | |
| SCHEMBL1162624 | 0.83 | NOS3 (0.50) | ITGB3ITGA2BANPEPENPEPSLC1A2 | |
| SCHEMBL180332 | 0.81 | SLC7A5 (0.57) | ITGB3ITGA2BMEN1KMT2ASLC1A3 | |
| SCHEMBL289162 | 0.81 | SLC7A5 (0.57) | ITGB3ITGA2BMEN1KMT2ASLC1A3 | |
| SCHEMBL180331 | 0.81 | SLC7A5 (0.57) | ITGB3ITGA2BMEN1KMT2ASLC1A3 | |
| SCHEMBL288308 | 0.80 | PRSS1 (0.51) | ITGB3ITGA2BANPEPENPEP | |
| SCHEMBL14686441 | 0.78 | ITGB3 (0.43) | ITGB3ITGA2BLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| EP-3087094-B1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | POLYPHOR AG (CH) | 2019-04-30 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-8865656-B2 | Beta-hairpin peptidomimetics having CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2014-10-21 | — | — | US | disclosed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| US-20120135942-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2012-05-31 | — | — | US | disclosed |
| EP-2427476-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | Polyphor Ag (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127704-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135942-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | CXCR4, CXCL12, CXCR6 | ITGB3 1766/4885ITGA2B 1299/4885ANPEP 115/4885 |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | SERPINB1, ELANE, XPNPEP1 | ITGB3 2715/4885ITGA2B 2660/4885ANPEP 61/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | ITGB3 1398/4885ITGA2B 3193/4885ANPEP 220/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | ITGB3 357/4885ITGA2B 547/4885ANPEP 3835/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | ITGB3 1398/4885ITGA2B 3193/4885ANPEP 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.